BDNF and focal segmental glomerulosclerosis: Li et al. posited the hypothesis that, in damaged podocytes, BDNF might contribute towards prolonging the podocyte processes, which contrasts with the flattening induced under nephrotic conditions both in vitro and in vivo, opening up a potential treatment option for damaged podocytes, especially in focal segmental glomerulosclerosis (FSGS) [14].